$QCRH

QCR Holdings, Inc. Announces Annual Meeting Results and a Cash Dividend of $0.10 Per Share

QCR Holdings, Inc. (NASDAQ: QCRH) said its May 21, 2026 annual meeting re-elected four Class III directors—James M. Field, John F. Griesemer, Elizabeth S. Jacobs, and Marie Z. Ziegler—to three-year terms. The board also declared a cash dividend of $0.10 per share, payable July 3, 2026 to holders of record June 18, 2026.

Original reporting
Published May 26, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
QCR Holdings, Inc. Announces Annual Meeting Results and a Cash Dividend of $0.10 Per Share — source image
Decision brief

The 30-second read

$QCRHBullishLow
01

Why it matters

For QCRH, the dividend declaration can support shareholder yield expectations, while director re-elections are typically neutral unless contested or signaling strategic change.

02

Market read

This is a routine corporate action/governance update with a clear dividend calendar catalyst but no new operating or credit information.

03

What to watch

Market reaction may depend on whether the dividend is consistent with prior payouts and on upcoming earnings/credit updates not covered here.

Relevance 6/10Timing: Dividend payable July 3, 2026; record date June 18, 2026 creates a predictable calendar catalyst.

Background

The company announced annual meeting results (re-election of four Class III directors) and declared a quarterly-style cash dividend with specified record and payable dates.

Company-level read

Ticker impact

$QCRHBullishMedium confidence
Context

QCR Holdings declared a $0.10/share cash dividend payable July 3, 2026, and reported annual meeting director re-elections.

Expected impact

Low-to-moderate positive drift around the declaration/record-date window; limited follow-through unless paired with earnings or guidance changes.

Evidence & confidence

The article contains capital return via a stated per-share dividend and governance updates, but no balance-sheet, credit, or earnings guidance changes.

Market effects

Adds a small data point on regional bank capital return, but lacks sector-wide guidance or regulatory developments.

Primarily affects investors focused on Midwest/Quad Cities regional banking; broader impact likely limited.

No direct global linkage beyond general bank equity income themes.

Counterpoint

Dividend size may be viewed as maintenance-level rather than growth, limiting upside beyond a short-term yield bid.

Key entities

  • QCR Holdings, Inc.

    Declared a $0.10 per share cash dividend and re-elected four Class III directors at its annual meeting.

Related articles

$QCRHMed

QCR Holdings, Inc. Announces Net Income of $36.3 million for the Second Quarter of 2026

QCR HOLDINGS INC (QCRH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qcrh-20260722xex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE FOR IMMEDIATE RELEASE ​ QCR Holdings, Inc. Announces Net Income of $36.3 million for the Second Quarter of 2026 ​ ​ Second Quarter 2026 Highlights ​ ● Net income of $36.3 million, or $2.19 diluted earnings per

$VALMedAI 8/10

Valaris secures $220 million in new drilling contracts

Valaris Limited (NYSE:VAL) announced $220 million in new drilling contracts, including deals with PETRONAS, INEOS, and Eni. Contracts span various regions and vessels, with start dates from late 2026 to 2030. The company also sold two rigs for recycling. According to Valaris, the contracts add to its backlog and include cost escalation mechanisms.

$PLSELowAI 8/10

Pulse Biosciences completes enrollment in cardiac ablation study

Pulse Biosciences (PLSE) completed enrollment in its NANOPULSE-AF Study for treating atrial fibrillation, hitting its 164-patient target three months early. The study evaluates the safety and effectiveness of its nPulse Cardiac Catheter System. Primary endpoints will be assessed at six and 12 months post-ablation. The company plans to share updates and present data at future conferences.

$BSXMed

Boston Scientific (BSX) Names Joseph Fitzgerald COO, Restructure

Boston Scientific (BSX) appointed Joseph M. Fitzgerald as COO, effective January 1, 2027, and restructured operations into three segments. The company is valued at $42.19, with a GF Value™ of $107.35, indicating a 60.7% undervaluation. BSX has a GF Score™ of 79, reflecting strong financial health and growth prospects, despite net insider selling and mixed guru activity.

$NVSMed

Novartis AG (NOT) Flags Phase III Remibrutinib MS Data, Plans Investor Call

Novartis AG will present late-breaking Phase III data for remibrutinib in relapsing multiple sclerosis (RMS) at MSToronto2026, with an investor call to follow. The company will also share new data for Kesimpta in pediatric MS, treatment-naive relapsing MS, and breastfeeding studies. According to the company, the data could influence approval prospects and portfolio value.

$BKVLow

BKV Corporation (BKV) Secures 1.2 GW Power Equipment With ~90% Cost Backstop

BKV Corporation signed a contract for 1.2 GW of gas-fired power equipment for a Texas project. The deal is backed by a hyperscaler agreement covering 90% of payments until March 31, 2027, with an option to terminate if no offtake is secured by that date. According to the company, this is part of their strategy to build a closed-loop gas-to-power platform with CCUS.